84-amino acid peptide hormone secreted by chief cells of the parathyroid glands in response to hypocalcemia. PTH orchestrates systemic Calcium Homeostasis through three coordinated mechanisms: mobilizing calcium from bone via indirect osteoclast activation, enhancing renal calcium reabsorption while increasing phosphate excretion, and promoting intestinal calcium absorption by stimulating Vitamin D hydroxylation to its active form (calcitriol).
Think of PTH as the emergency dispatch system for a city's calcium supply network. When the blood calcium reservoir drops below critical levels (like a water tower running low), calcium-sensing receptors on the parathyroid glands detect the shortage and immediately radio PTH dispatch units. These dispatchers send three types of emergency crews: bone demolition teams that carefully dismantle old calcium-containing structures (bone resorption), kidney plumbers who tighten the calcium drains to prevent loss while opening the phosphate drains wider (conserving calcium, dumping phosphate), and activation engineers who convert inactive vitamin D warehouses into active calcium-loading stations in the gut. The system is elegant under acute stress—like calling in reserves during a water shortage—but becomes destructive when the alarm never stops: chronic PTH elevation is like continuously demolishing buildings to supply water to a leaking reservoir, eventually weakening the entire city's infrastructure (osteoporosis, vascular calcification). The root problem isn't the dispatch system—it's the chronic shortage that keeps the alarm blaring.
PTH secretion and action follow a multi-system cascade:
Secretion Trigger:
- Parathyroid chief cell calcium-sensing receptors (CaSR) detect decreased serum ionized Ca²⁺ (<1.15 mmol/L)
- CaSR deactivation → decreased intracellular cAMP → disinhibition of PTH gene transcription
- Pre-pro-PTH synthesized → cleaved to pro-PTH → mature 84-amino acid PTH
- Magnesium required as CaSR cofactor and for PTH secretion machinery
Bone Target:
- PTH binds PTHR1 (PTH receptor type 1) on Osteoblasts
- PTHR1 activation → Gαs protein → adenylyl cyclase → ↑cAMP → PKA activation
- Osteoblasts upregulate RANKL (receptor activator of NF-κB ligand)
- RANKL binds RANK on osteoclast precursors → NF-κB pathway activation
- Mature osteoclasts increase bone resorption, releasing Calcium and phosphate into blood
- Osteoblasts decrease osteoprotegerin (OPG), removing brake on osteoclast formation
Kidney Target:
- PTH → PTHR1 on distal tubule cells → cAMP/PKA pathway
- Increased Calcium reabsorption via TRPV5 channels and NCX1 exchangers in distal convoluted tubule
- Decreased phosphate reabsorption via NPT2a/NPT2c downregulation in proximal tubule
- Activation of 1α-hydroxylase (CYP27B1) enzyme
- Converts 25-OH Vitamin D → 1,25-OH vitamin D (calcitriol) in proximal tubule mitochondria
Intestinal Target (Indirect):
- Calcitriol → vitamin D receptor (VDR) in enterocytes
- VDR-RXR complex → transcription of calcium transport genes
- ↑TRPV6, calbindin-D9k, NCX1 → increased dietary calcium absorption
- Effect manifest within 24-48 hours
graph TD
A["Low Serum Ca²⁺ <1.15 mmol/L"] --> B[Parathyroid CaSR Deactivation]
B --> C[PTH Secretion]
C --> D["Bone: PTHR1 on Osteoblasts"]
C --> E["Kidney: PTHR1 on Tubule Cells"]
D --> D1["↑RANKL/↓OPG"]
D1 --> D2[Osteoclast Activation]
D2 --> D3["Bone Resorption → ↑Ca²⁺ ↑PO₄³⁻"]
E --> E1["Distal Tubule: ↑Ca²⁺ Reabsorption"]
E --> E2["Proximal Tubule: ↓PO₄³⁻ Reabsorption"]
E --> E3["↑1α-hydroxylase Activity"]
E3 --> F["25-OH Vit D → 1,25-OH Vit D"]
F --> G[Intestinal VDR Activation]
G --> H["↑Calcium Absorption Genes"]
H --> I["↑Dietary Ca²⁺ Uptake"]
D3 --> J["Restore Serum Ca²⁺"]
E1 --> J
I --> J
J --> K["Negative Feedback: ↓PTH Secretion"]
style A fill:#ffcccc
style J fill:#ccffcc
style K fill:#cce5ff
Negative Feedback:
- Rising Ca²⁺ → CaSR reactivation → ↓PTH
- Calcitriol → PTH gene suppression (genomic effect)
- FGF23 from bone → ↓1α-hydroxylase, limiting calcitriol production
PTH dysregulation is central to multiple cPNI pathologies and represents a critical convergence of the Metabolic System, musculoskeletal integrity, and immune-bone crosstalk.
Primary Pathological States:
Secondary Hyperparathyroidism (chronic PTH elevation despite normal glands):
- Vitamin D deficiency (<30 ng/mL 25-OH D) is the most common trigger—insufficient calcitriol fails to suppress PTH and limits intestinal calcium absorption
- Chronic Kidney Disease (eGFR <60): impaired phosphate excretion and 1α-hydroxylase activity create dual PTH stimulus
- chronic latent acidosis: protons buffered by bone calcium release, sensed as hypocalcemia, driving compensatory PTH secretion—this represents Mismatch Disease, as chronic acid load from modern diets (high protein, low plant intake) was rare in evolutionary contexts
- Magnesium deficiency (<1.8 mg/dL): impairs both PTH secretion AND end-organ response, creating functional hypoparathyroidism followed by rebound hyperparathyroidism when corrected
Clinical Presentations:
- Osteoporosis/Stress fractures: chronic bone resorption depletes calcium reserves, weakens trabecular architecture
- Poor wound healing/fracture non-union: calcium signaling essential for Collagen biosynthesis pathway and osteoblast differentiation
- Chronic pain: bone resorption releases inflammatory mediators; calcium dysregulation affects neuronal excitability
- Vascular calcification: chronic hyperphosphatemia and calcium-phosphate product >55 mg²/dL² drives ectopic calcification, especially in CVD patients
- Chronic fatigue syndrome: calcium-dependent mitochondrial function compromised; muscle weakness from hypocalcemia or hypercalcemia
Metamodel Connections:
- Selfish Systems: Bone sacrificed to maintain blood calcium (brain, heart priority)—Selfish Brain demands stable calcium for neuronal function, triggering PTH-mediated bone raiding
- Evolutionary Mismatch: High dietary acid load, low Vitamin D (indoor living), high phosphate intake (processed foods) create chronic PTH drive unprecedented in ancestral environments
- Intermittent Living Violation: Constant feeding (especially high protein without compensatory plants) maintains acid load and PTH elevation; ancestral feast-famine cycles allowed PTH normalization
Clinical Thresholds:
- Normal PTH: 10-65 pg/mL (assay-dependent; intact PTH most common)
- Secondary hyperparathyroidism suggested: PTH >65 pg/mL with normal/low calcium
- Target 25-OH Vitamin D: >40 ng/mL to suppress PTH optimally (>30 ng/mL minimum)
- Calcium-phosphate product: keep <55 mg²/dL² to prevent calcification
- Magnesium: optimize to 2.0-2.5 mg/dL before interpreting PTH
Intervention Implications:
- Root Cause Correction: Address Vitamin D deficiency (5,000-10,000 IU daily until >40 ng/mL), Magnesium repletion (400-800 mg glycinate/malate), dietary acid load reduction (increase vegetable intake, moderate protein)
- Bone Protection: Ensure adequate dietary Calcium (1,000-1,200 mg/day from food preferably), vitamin K2 (directs calcium to bone, away from vessels), weight-bearing Exercise
- Kidney Function: Monitor eGFR; manage phosphate if CKD present
- Chronic Pain Context: PTH-driven bone pain may masquerade as fibromyalgia or inflammatory arthritis—check 25-OH D, PTH, Magnesium in persistent musculoskeletal pain
- PTH is an 84-amino acid peptide with half-life of 2-4 minutes in circulation
- Normal range: 10-65 pg/mL (varies by assay; use same lab for serial monitoring)
- Secreted by chief cells of 4 parathyroid glands (posterior to thyroid)
- Calcium-sensing receptor (CaSR) threshold: PTH secretion increases sharply when ionized Ca²⁺ drops below 1.15 mmol/L (4.6 mg/dL)
- PTH increases serum calcium by 0.5-1.0 mg/dL acutely; decreases phosphate by enhancing renal excretion (fractional excretion of phosphate increases to 15-20%)
- Bone resorption effect visible within 3-6 hours; peak bone calcium release at 12-24 hours
- Vitamin D activation requires 1-3 days for full effect (genomic mechanism)
- Magnesium required for PTH secretion (severe hypomagnesemia causes functional hypoparathyroidism); also required for PTHR1 receptor signaling
- Chronic PTH elevation (months-years) causes cortical bone thinning, trabecular bone loss, increased fracture risk by 2-3 fold
- Intermittent PTH (anabolic dosing: teriparatide 20 mcg daily SC) stimulates osteoblast activity; continuous PTH (hyperparathyroidism) is catabolic to bone
- PTHR1 also present in growth plate chondrocytes, regulating skeletal development
- PTH gene on chromosome 11; mutations rare but cause familial hypocalcemic hypercalciuria
- Calcium — primary regulatory target; PTH restores serum calcium from bone, kidney, gut
- Ca²⁺ — ionized calcium specifically detected by parathyroid CaSR; triggers PTH secretion below 1.15 mmol/L
- Vitamin D — PTH stimulates 1α-hydroxylase to activate 25-OH D to calcitriol, which then suppresses PTH (negative feedback loop)
- Magnesium — essential cofactor for CaSR function, PTH secretion, and PTHR1 signaling; deficiency causes PTH resistance then rebound hyperparathyroidism
- Osteoblasts — express PTHR1; PTH binding induces RANKL secretion to activate osteoclasts indirectly
- osteoclast — bone-resorbing cells activated by osteoblast-derived RANKL in response to PTH; release calcium and phosphate
- bone metabolism — PTH is the primary acute regulator, favoring resorption under chronic elevation
- Osteoporosis — chronic PTH excess depletes bone mineral density, particularly cortical bone; hallmark of untreated secondary hyperparathyroidism
- Chronic Kidney Disease — impaired phosphate excretion and loss of 1α-hydroxylase drive secondary hyperparathyroidism; PTH often >100-200 pg/mL in advanced CKD
- phosphate — PTH decreases serum phosphate by inhibiting NPT2a/NPT2c renal transporters; calcium-phosphate product critical for calcification risk
- chronic latent acidosis — chronic acid load buffers with bone calcium, sensed as hypocalcemia, driving compensatory PTH elevation
- Collagen biosynthesis pathway — calcium signaling (regulated by PTH) required for proline/lysine hydroxylation and collagen crosslinking
- wound healing — calcium-dependent processes (clotting, cell migration, matrix synthesis) impaired by PTH dysregulation
- Stress fractures — chronic PTH elevation weakens bone microarchitecture; common in vitamin D-deficient athletes or postmenopausal women
- inflammation — bone resorption releases inflammatory mediators; PTH-calcium axis dysregulation contributes to chronic inflammation
- PTHrP — parathyroid hormone-related peptide; shares PTHR1 but distinct physiological role (paracrine vs endocrine); elevated in malignancy-associated hypercalcemia
- Metabolic System — PTH integrates calcium, phosphate, vitamin D metabolism; dysregulation reflects systemic metabolic failure
- Selfish Brain — brain prioritizes stable calcium for neurotransmission, driving PTH-mediated bone calcium mobilization regardless of skeletal cost
- Mismatch Disease — modern diet (high acid, low vitamin D, high phosphate) creates chronic PTH drive; ancestral diets were alkaline, low phosphate, high sun exposure
- Exercise — weight-bearing exercise opposes PTH-driven bone loss by stimulating osteoblast activity; essential intervention for hyperparathyroidism
- Homeostasis — PTH is central to calcium homeostasis; chronic activation represents homeostatic failure, not adaptation
- CVD — chronic hyperparathyroidism associated with vascular calcification, hypertension, left ventricular hypertrophy
- Insulin resistance — bidirectional relationship; hyperparathyroidism impairs insulin sensitivity; insulin resistance worsens vitamin D metabolism